MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory cancers: An open-label, phase 1 dose-escalation and expansion study

The Lancet Oncology

Volumn 15, Issue 6, 2014, Pages 656-666

  Hong, David S ^a   Hui, David ^a   Bruera, Eduardo ^a   Janku, Filip ^a   Naing, Aung ^a   Falchook, Gerald S ^a   Piha Paul, Sarina ^a   Wheler, Jennifer J ^a   Fu, Siqing ^a   Tsimberidou, Apostolia M ^a   Stecher, Michael ^b   Mohanty, Prasant ^b   Simard, John ^b   Kurzrock, Razelle ^c  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Department of Palliative Care and Rehabilitation Medicine MD Anderson Cancer Center ^*  (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTATE AMINOTRANSFERASE; INTERLEUKIN 1ALPHA; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY P1; UNCLASSIFIED DRUG;

ACUTE KIDNEY FAILURE; ADULT; AGED; ANEMIA; ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BODY COMPOSITION; CANCER STAGING; COLORECTAL CANCER; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; EAR DISEASE; FATIGUE; FEMALE; FOCAL EPILEPSY; HEADACHE; HUMAN; HYPERKALEMIA; HYPOALBUMINEMIA; INTRACTABLE PAIN; KIDNEY CANCER; LEAN BODY WEIGHT; LEG CRAMP; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MUSCLE CRAMP; NASOPHARYNX CANCER; NAUSEA; PANCREAS CANCER; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEINURIA; QUALITY OF LIFE; THROMBOCYTOPENIA; THYROID CANCER; UNSPECIFIED SIDE EFFECT; VOMITING; WEAKNESS; WEIGHT CHANGE;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INTERLEUKIN-1ALPHA; KAPLAN-MEIER ESTIMATE; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; TREATMENT OUTCOME;

EID: 84899989426     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(14)70155-X     Document Type: Article

References (44)

1. Solheim TS, Fearon KC, Blum D, Kaasa S Non-steroidal anti-inflammatory treatment in cancer cachexia: a systematic literature review. Acta Oncol 2013, 52:6-17.
2. Dinarello CA, Simon A, van der Meer JW Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov 2012, 11:633-652.
3. Matsuo Y, Sawai H, Ma J, et al. IL-1alpha secreted by colon cancer cells enhances angiogenesis: the relationship between IL-1alpha release and tumor cells' potential for liver metastasis. J Surg Oncol 2009, 99:361-367.
4. Matsuo Y, Sawai H, Ochi N, et al. Interleukin-1 alpha secreted by pancreatic cancer cells promotes angiogenesis and its therapeutic implications. J Surg Res 2009, 153:274-281.
5. Voronov E, Shouval DS, Krelin Y, et al. IL-1 is required for tumor invasiveness and angiogenesis. Proc Natl Acad Sci USA 2003, 100:2645-2650.
6. Tomimatsu S, Ichikura T, Mochizuki H Significant correlation between expression of interleukin-1alpha and liver metastasis in gastric carcinoma. Cancer 2001, 91:1272-1276.
7. Singer CF, Kronsteiner N, Hudelist G, et al. Interleukin 1 system and sex steroid receptor expression in human breast cancer: interleukin 1alpha protein secretion is correlated with malignant phenotype. Clin Cancer Res 2003, 9:4833-4877.
8. Ling J, Kang Y, Zhao R, et al. Kras G12D-induced IKK2/β/NF-κB activation by IL-1α and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma. Cancer Cell 2012, 21:105-120.
9. Stone RL, Nick AM, McNeish IA, et al. Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med 2012, 366:610-618.
10. Kaji M, Ishikura H, Kishimoto T, et al. E-selectin expression induced by pancreas-carcinoma-derived interleukin-1 alpha results in enhanced adhesion of pancreas-carcinoma cells to endothelial cells. Int J Cancer 1995, 60:712-717.
11. Sawai H, Takeyama H, Yamamoto M, et al. Enhancement of integrins by interleukin-1alpha, and their relationship with metastatic and invasive behavior of human pancreatic ductal adenocarcinoma cells. J Surg Oncol 2003, 82:51-56.
12. Sawai H, Funahashi H, Yamamoto M, et al. Interleukin-1 alpha enhances integrin alpha(6)beta(1) expression and metastatic capability of human pancreatic cancer. Oncology 2003, 65:167-173.
13. Scherbarth S, Orr FW Intravital videomicroscopic evidence for regulation of metastasis by the hepatic microvasculature: effects of interleukin-1alpha on metastasis and the location of B16F1 melanoma cell arrest. Cancer Res 1997, 57:4105-4110.
14. Guijarro A, Laviano A, Meguid MM Hypothalamic integration of immune function and metabolism. Prog Brain Res 2006, 153:367-405.
15. Braun TP, Zhu X, Szumowski M, et al. Central nervous system inflammation induces muscle atrophy via activation of the hypothalamic-pituitary-adrenal axis. J Exp Med 2011, 208:2449-2463.
16. Garrone P, Djossou O, Fossiez F, et al. Generation and characterization of a human monoclonal autoantibody that acts as a high affinity interleukin-1α specific inhibitor. Mol Immunol 1996, 33:649-658.
17. Wolchok JD, Hoos A, O'Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009, 15:7412-7420.
18. Wang Z, Heymsfield SB, Chen Z, Zhu S, Pierson RN Estimation of percentage body fat by dual-energy x-ray absorptiometry: evaluation by in vivo human elemental composition. Phys Med Biol 2010, 55:2619-2635.
19. Toombs RJ, Ducher G, Shepherd JA, De Souza MJ The impact of recent technological advances on the trueness and precision of DXA to assess body composition. Obesity (Silver Spring) 2012, 20:30-39.
20. White SL, Yu R, Craig JC, Polkinghorne KR, Atkins RC, Chadban SJ Diagnostic accuracy of urine dipsticks for detection of albuminuria in the general community. Am J Kidney Dis 2011, 58:19-28.
21. Dirks NL, Meibohm B Population pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet 2010, 49:633-659.
22. Bernstein SH, Fay J, Frankel S, et al. A phase I study of recombinant human soluble interleukin-1 receptor (rhu IL-1R) in patients with relapsed and refractory acute myeloid leukemia. Cancer Chemother Pharmacol 1999, 43:141-144.
23. Smith JW, Longo DL, Alvord WG, et al. The effects of treatment with interleukin-1 alpha on platelet recovery after high-dose carboplatin. N Engl J Med 1993, 328:756-761.
24. Smith JW, Urba WJ, Curti BD, et al. The toxic and hematologic effects of interleukin-1 alpha administered in a phase I trial to patients with advanced malignancies. J Clin Oncol 1992, 10:1141-1152.
25. Weisdorf D, Katsanis E, Verfaillie C, et al. Interleukin-1 alpha administered after autologous transplantation: a phase I/II clinical trial. Blood 1994, 84:2044-2049.
26. Reuben DB, Mor V, Hiris J Clinical symptoms of survival in patients with terminal cancer. Arch Intern Med 1988, 148:1586-1591.
27. Vigano A, Dorgan M, Buckingham J, Bruera E, Suarez-Almazor ME Survival prediction in terminal cancer patients: a systematic review of the medical literature. Palliat Med 2000, 14:363-374.
28. Vigano A, Donaldson N, Higginson IJ, Bruera E, Mahmud S, Suarez-Almazor M Quality of life and survival prediction in terminal cancer patients: a multicenter study. Cancer 2004, 101:1090-1098.
29. Dewys WD, Begg C, Lavin PT, et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med 1980, 69:491-497.
30. Thornton P, McColl BW, Greenhalgh A, Denes A, Allan SM, Rothwell NJ Platelet interleukin-1alpha drives cerebrovascular inflammation. Blood 2010, 115:3632-3639.
31. Tosato G, Jones KD Interleukin-1 induces interleukin-6 production in peripheral blood monocytes. Blood 1990, 75:1305-1310.
32. Bayliss TJ, Smith JT, Schuster M, Dragnev KH, Rigas JR A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer. Expert Opin Biol Ther 2011, 11:1663-1668.
33. Trikha M, Corringham R, Klein B, Rossi JF Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin Cancer Res 2003, 9:4653-4665.
34. Beaupre DM, Talpaz M, Marini FC, et al. Autocrine interleukin-1beta production in leukemia: evidence for the involvement of mutated RAS. Cancer Res 1999, 59:2971-2980.
35. Ling J, Kang Y, Zhao R, et al. KrasG12D-induced IKK2/β/NF-κB activation by IL-1α and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma. Cancer Cell 2012, 21:105-120.
36. Benjamin RS, Choi H, Macapinlac HA, et al. We should desist using RECIST, at least in GIST. J Clin Oncol 2007, 25:1760-1764.
37. Murdoch C, Muthana M, Coffelt SB, Lewis CE The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer 2008, 8:618-631.
38. Allevena P, Mantovani A Immunology in the clinic review series; focus on cancer: tumour-associated macrophages: undisputed stars of the inflammatory tumour microenvironment. Clin Exp Immunol 2012, 167:195-205.
39. McDermott DF, Atkins MB PD-1 as a potential target in cancer therapy. Cancer Med 2013, 2:662-673.
40. Baracos V, Rodemann HP, Dinarello CA, Goldberg AL Stimulation of muscle protein degradation and prostaglandin E2 release by leukocytic pyrogen (interleukin-1). A mechanism for the increased degradation of muscle proteins during fever. N Engl J Med 1983, 308:553-558.
41. 2+, and leukocytic pyrogen (interleukin 1). Fed Proc 1984, 43:1301-1306.
42. Grothey A, Sobrero AF, Siena S, et al. Results of a phase III randomized, double-blind, placebo-controlled, multicenter trial (CORRECT) of regorafenib plus best supportive care (BSC) versus placebo plus BSC in patients (pts) with metastatic colorectal cancer (mCRC) who have progressed after standard therapies. Proc Am Soc Clin Oncol 2012, 30(suppl 4). LBA385 (abstr).
43. Jonker DJ, O'Callaghan CJ, Karapetis CS, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007, 357:2040-2048.
44. Shitara K, Matsuo K, Yokota T, et al. Prognostic factors for metastatic colorectal cancer patients undergoing irinotecan-based second-line chemotherapy. Gastrointest Cancer Res 2011, 4:168-172.